Recent advances in the understanding and treatment of acute myeloid leukemia

Research output: Contribution to journalReview article

11 Scopus citations

Abstract

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that has a poor prognosis. Recent advances in genomics and molecular biology have led to a greatly improved understanding of the disease. Until 2017, there had been no new drugs approved for AML in decades. Here, we review novel drug targets in AML with a focus on epigenetic-targeted therapies in pre-clinical and clinical development as well as the recent new drug approvals.

Original languageEnglish (US)
Article number1196
JournalF1000Research
Volume7
DOIs
StatePublished - Jan 1 2018

    Fingerprint

Keywords

  • Acute myeloid leukemia (AML); genomics; epigenetics; targeted therapies; drug development

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this